Omeros (NASDAQ:OMER)

CAPS Rating: 2 out of 5

Results 1 - 11 of 11

Recs

0
Member Avatar marsuculix (53.32) Submitted: 3/3/2015 8:52:16 AM : Outperform Start Price: $24.96 OMER Score: +6.05

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2 (a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system).

Recs

0
Member Avatar Bobmoll36 (49.38) Submitted: 11/17/2014 1:38:23 PM : Outperform Start Price: $19.69 OMER Score: +30.87

in at 13. Rising well. good drug history

Recs

0
Member Avatar fdgaley (< 20) Submitted: 8/12/2014 5:13:29 PM : Outperform Start Price: $12.79 OMER Score: +99.90

Great Pipeline.

Recs

0
Member Avatar griderX (97.26) Submitted: 6/3/2014 10:12:34 AM : Outperform Start Price: $11.43 OMER Score: +121.33

Speculative Buy List

Recs

2
Member Avatar zzlangerhans (99.82) Submitted: 4/8/2014 12:34:14 AM : Outperform Start Price: $11.00 OMER Score: +125.32

Perhaps the secret PDUFA date for Omidria is keeping Omeros off run-up traders' catalyst calendars. The stock has been decidedly weak ahead of the FDA approval decision, which I project will occur in early June. Meanwhile, Omeros is attempting to escape from their grimy repurposer past with sexier new chemical entities OMS721 and OMS824. With a powerful catalyst approaching and a newly strengthened pipeline, Omeros could be a force to reckon with if the biopharma sector snaps out of its recent funk.

Recs

0
Member Avatar kcprojects (< 20) Submitted: 12/19/2013 6:41:16 PM : Outperform Start Price: $10.16 OMER Score: +142.86

FDA approval

Recs

0
Member Avatar pcguy (< 20) Submitted: 11/23/2013 2:42:56 AM : Outperform Start Price: $7.20 OMER Score: +249.78

FDA approval.

Recs

0
Member Avatar stover87 (23.42) Submitted: 2/4/2013 10:13:54 AM : Outperform Start Price: $5.61 OMER Score: +329.63

Q! 2013 NDA filing and mid 2013 filing in europe, looking very postive and phase 3 results exceeded expectations.

Recs

0
Member Avatar fox2man2 (< 20) Submitted: 10/6/2012 12:38:50 AM : Outperform Start Price: $10.29 OMER Score: +111.53

I believe OMER will outperform the S&P 500 by a considerable amount. I encourage Fools to go to its website and read about recent developments in its propieteray medical programs. That is a 15 minute task and well worth one's time. OMER has no income at this time, but expects approval of two drugs in 2013, one for arthroscopic knee surgery and a second for eye surgery. Daily trading volume has been small, however, and this should be considered by prospective investors.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 4/1/2011 11:03:52 AM : Underperform Start Price: $5.17 OMER Score: -352.08

this a warning for all beginners! why? so you can put the money in my stocks and so drive my winnings

Recs

0
Member Avatar cwstrand (< 20) Submitted: 10/21/2009 12:16:46 AM : Outperform Start Price: $6.85 OMER Score: +191.66

The patents this company holds are incredible. The breakthrough in patient treatment for pain post-surgery (in clinical trials) is outstanding for arthro, eye, uro, etc. are oustanding. Once any of the trials, in various phases now, hits, this will blow sky high.

Results 1 - 11 of 11

Featured Broker Partners


Advertisement